These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 10570020

  • 1. Enhancement of platinum-drug cytotoxicity in a human head and neck squamous cell carcinoma line and its platinum-resistant variant by liposomal amphotericin B and phospholipase A2-II.
    Ferguson PJ, Currie C, Vincent MD.
    Drug Metab Dispos; 1999 Dec; 27(12):1399-405. PubMed ID: 10570020
    [Abstract] [Full Text] [Related]

  • 2. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
    Sharp SY, Mistry P, Valenti MR, Bryant AP, Kelland LR.
    Cancer Chemother Pharmacol; 1994 Dec; 35(2):137-43. PubMed ID: 7987990
    [Abstract] [Full Text] [Related]

  • 3. Potentiation of cisplatin and carboplatin cytotoxicity by amphotericin B in different human ovarian carcinoma and malignant peritoneal mesothelioma cells.
    Poulain L, Sichel F, Crouet H, Bureau F, Gauduchon P, Gignoux M, Le Talaër JY.
    Cancer Chemother Pharmacol; 1997 Dec; 40(5):385-90. PubMed ID: 9272114
    [Abstract] [Full Text] [Related]

  • 4. Potentiating effect of amphotericin B on five platinum anticancer drugs in human cis-diamminedichloroplatinum (II) sensitive and resistant ovarian carcinoma cells.
    Kikkawa F, Kojima M, Oguchi H, Maeda O, Ishikawa H, Tamakoshi K, Mizuno K, Kawai M, Suganuma N, Tomoda Y.
    Anticancer Res; 1993 Dec; 13(4):891-6. PubMed ID: 8352556
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).
    Teicher BA, Holden SA, Kelley MJ, Shea TC, Cucchi CA, Rosowsky A, Henner WD, Frei E.
    Cancer Res; 1987 Jan 15; 47(2):388-93. PubMed ID: 3539321
    [Abstract] [Full Text] [Related]

  • 10. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.
    Clin Cancer Res; 1997 Nov 15; 3(11):2063-74. PubMed ID: 9815598
    [Abstract] [Full Text] [Related]

  • 11. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
    Knox RJ, Friedlos F, Lydall DA, Roberts JJ.
    Cancer Res; 1986 Apr 15; 46(4 Pt 2):1972-9. PubMed ID: 3512077
    [Abstract] [Full Text] [Related]

  • 12. [Pharmacological approach to the platinum compounds].
    Sasaki Y.
    Gan To Kagaku Ryoho; 1992 Apr 15; 19(4):456-62. PubMed ID: 1313667
    [Abstract] [Full Text] [Related]

  • 13. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C, Bettio F, Baccichetti F, Trevisan A, Giovagnini L, Fregona D.
    Chem Biol Interact; 2004 Jun 30; 148(1-2):37-48. PubMed ID: 15223355
    [Abstract] [Full Text] [Related]

  • 14. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.
    Groen HJ, Sleijfer S, Meijer C, Kampinga HH, Konings AW, De Vries EG, Mulder NH.
    Br J Cancer; 1995 Dec 30; 72(6):1406-11. PubMed ID: 8519652
    [Abstract] [Full Text] [Related]

  • 15. In vitro and in vivo antineoplastic activity of a new platinum antineoplastic agent, (R)-(-)-1,1-cyclobutanedicarboxylate (2-aminomethylpyrrolidine)-platinum (II) (DWA2114R) on freshly separated human tumor cells and human tumor xenografts transplanted in nude mice--a comparison with cis-diammine-dichloroplatinum (CDDP).
    Nio Y, Imai S, Shiraishi T, Tsubono M, Morimoto H, Tseng CC, Tobe T.
    Anticancer Res; 1991 Dec 30; 11(2):761-7. PubMed ID: 2064331
    [Abstract] [Full Text] [Related]

  • 16. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR.
    Cancer Res; 1993 Jun 01; 53(11):2581-6. PubMed ID: 8388318
    [Abstract] [Full Text] [Related]

  • 17. Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells.
    Cho YL, Christensen C, Saunders DE, Lawrence WD, Deppe G, Malviya VK, Malone JM.
    Cancer Res; 1991 Jun 01; 51(11):2848-53. PubMed ID: 2032225
    [Abstract] [Full Text] [Related]

  • 18. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W, Chaney SG.
    Cancer Res; 1993 Feb 15; 53(4):799-805. PubMed ID: 8428361
    [Abstract] [Full Text] [Related]

  • 19. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
    Ohmori T, Morikage T, Sugimoto Y, Fujiwara Y, Kasahara K, Nishio K, Ohta S, Sasaki Y, Takahashi T, Saijo N.
    Jpn J Cancer Res; 1993 Jan 15; 84(1):83-92. PubMed ID: 8383649
    [Abstract] [Full Text] [Related]

  • 20. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N, Lam YM, Pym J, Campling BG.
    Cancer; 1996 May 01; 77(9):1797-808. PubMed ID: 8646677
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.